Analysts Issue Forecasts for Kodiak Sciences Q1 Earnings

Kodiak Sciences Inc. (NASDAQ:KOD - Free Report) - Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of Kodiak Sciences in a research report issued on Monday, March 31st. HC Wainwright analyst M. Caufield anticipates that the company will post earnings per share of ($0.90) for the quarter. HC Wainwright has a "Neutral" rating and a $3.00 price target on the stock. The consensus estimate for Kodiak Sciences' current full-year earnings is ($3.45) per share. HC Wainwright also issued estimates for Kodiak Sciences' FY2029 earnings at ($1.51) EPS.

Kodiak Sciences (NASDAQ:KOD - Get Free Report) last released its earnings results on Thursday, March 27th. The company reported ($0.84) earnings per share for the quarter, topping analysts' consensus estimates of ($0.90) by $0.06.

Separately, Jefferies Financial Group raised shares of Kodiak Sciences from a "hold" rating to a "buy" rating and set a $20.00 price target for the company in a report on Monday, December 9th.

Kodiak Sciences Price Performance

Shares of Kodiak Sciences stock traded down $0.05 during trading on Wednesday, hitting $2.35. The stock had a trading volume of 541,890 shares, compared to its average volume of 342,560. The business has a fifty day moving average of $4.32 and a two-hundred day moving average of $5.42. Kodiak Sciences has a fifty-two week low of $2.10 and a fifty-two week high of $11.60. The firm has a market cap of $123.96 million, a P/E ratio of -0.64 and a beta of 2.40.

Institutional Investors Weigh In On Kodiak Sciences

Several hedge funds have recently modified their holdings of KOD. Barclays PLC boosted its stake in Kodiak Sciences by 65.5% in the 3rd quarter. Barclays PLC now owns 79,658 shares of the company's stock worth $208,000 after purchasing an additional 31,527 shares during the period. JPMorgan Chase & Co. boosted its position in shares of Kodiak Sciences by 220.9% in the third quarter. JPMorgan Chase & Co. now owns 44,648 shares of the company's stock worth $117,000 after buying an additional 30,735 shares during the period. FMR LLC grew its holdings in shares of Kodiak Sciences by 26.4% during the third quarter. FMR LLC now owns 200,971 shares of the company's stock valued at $525,000 after buying an additional 41,987 shares in the last quarter. State Street Corp raised its position in Kodiak Sciences by 1.8% during the third quarter. State Street Corp now owns 816,634 shares of the company's stock valued at $2,131,000 after buying an additional 14,711 shares during the period. Finally, Peapod Lane Capital LLC purchased a new stake in Kodiak Sciences in the 4th quarter worth about $1,660,000. 89.06% of the stock is owned by hedge funds and other institutional investors.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy.